Dawu Ventures
达武创投
Dawu Ventures (达武创投) is a Chinese venture capital firm that appears as a co-investor in early-stage deals. The fund participated in Nexic's Series B round alongside BlueRun Ventures and others in early 2023 , and joined Kelan Medicine's oversubscribed Series A financing of over 100 million RMB led by Gaorong Capital in mid-2023 . Elsewhere's corpus does not cover Dawu Ventures' own founding story, fund size, or investment strategy in depth — the available material only captures its activity as a participant in other firms' announced rounds.
AI-generated — may contain errors, please verify.
Coverage
Liang Jun's First Year at the Helm: Fangqing Tech Raises Over 500 Million RMB in Three Rounds Within Six Months
A star-studded lineup of shareholders quickly assembled.
Kailan Pharma Closes Oversubscribed Series A Financing of Over 100 Million RMB to Advance Innovative Drug Development in Cholesterol Metabolism
Gaorong Ventures led the round.
BlueRun Ventures Continues to Double Down, SG DevTech Secures Hundreds of Millions of RMB in Series B Funding | BlueRun Ventures
Building a leading domestic manufacturer of silicon carbide (SiC) power device chips
